Pirfenidone: Is it Really a Game Changer for Pulmonary Fibrosis?
"Unpacking the Effectiveness and Tolerability of Pirfenidone in Treating Idiopathic Pulmonary Fibrosis"
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that progressively scars the lungs, making it difficult to breathe. While there's no cure, pirfenidone is a medication used to slow down the progression of the disease. But how effective is it in the real world, and what side effects should patients and caregivers be aware of?
Two studies presented at a pharmacy conference shed light on these important questions. One study examines the effectiveness and safety of pirfenidone in patients with mild to moderate IPF, while the other investigates the adverse events associated with the drug and the reasons why some patients discontinue treatment.
This article synthesizes the findings of these studies to provide a clear and accessible overview of pirfenidone's role in managing IPF, offering practical insights for patients, families, and healthcare providers.
Available IPF Medicines
Drugs.com lists pirfenidone and nintedanib (Ofev) as prescription-only alternatives for idiopathic pulmonary fibrosis (IPF). It also lists Esbriet as a brand name for pirfenidone. The source identifies these medicines as options prescribed for IPF but provides no prevalence, survival, or treatment-effect statistics.
Treatment Evidence and Limits
IPF is described as a progressive disease with a poor prognosis; one review reports a median survival time of 2–5 years. A 2015 systematic review says pirfenidone showed benefit in limiting decline in forced vital capacity (FVC) and improving progression-free survival, while the 2024 real-world review describes it as associated with increased progression-free and overall survival. These sources also note limitations: treatment can cause multiple side effects, and earlier searches for effective treatments involved investigational agents without significant success.
Changing Views of IPF and Pirfenidone
A 2006 clinical review described IPF as a devastating disease with median mortality of only 3 years and noted that its incidence was rising. A 2020 review discusses progress in understanding IPF pathogenesis and a conceptual change in how the disease is understood. A 2026 review reports that pirfenidone was first synthesized as an anti-inflammatory agent and was later identified as the first oral antifibrotic therapy to improve progression-free survival in IPF.
Pirfenidone's Impact on Lung Function: What the Studies Reveal
One study retrospectively looked at the effects of pirfenidone on lung function in eight patients with mild to moderate IPF. The researchers primarily focused on changes in forced vital capacity (FVC), a measure of how much air a person can exhale forcefully after a deep breath. FVC is a key indicator of lung function in IPF patients.
- Five patients experienced an increase in FVC, indicating improved lung function.
- Three patients showed a decrease in FVC, suggesting the disease was still progressing despite treatment.
- Other lung function variables, like forced expiratory volume (FEV1) and diffusion capacity for carbon monoxide (DLCO), were not consistently recorded for all patients, limiting the ability to draw broader conclusions.
- Two patients with available data showed some improvement in their ability to walk for six minutes (6MWT), alongside a decline in DLCO.
Recent Evidence Across Studies
A systematic review and meta-analysis included 74 real-world studies examining pirfenidone and nintedanib in people with IPF. A separate review characterizes pirfenidone as a cornerstone treatment for fibrotic interstitial lung diseases, particularly IPF, and reviews its mechanisms, clinical efficacy, safety, and potential applications beyond IPF. A July 2026 Bayesian network meta-analysis comparing nintedanib and pirfenidone reports that its results suggest pirfenidone is superior in slowing lung-function decline.
Uncertainty in the Evidence
A systematic review of pirfenidone in progressive pulmonary fibrosis cautions that certainty in the estimated effects is very low. The review attributes this uncertainty to limitations in the available evidence. Its finding therefore calls for caution in interpreting estimated treatment effects from that evidence.
Pirfenidone and Nintedanib
A source on IPF treatments identifies nintedanib and pirfenidone as the two approved antifibrotics and estimates that IPF affects approximately 3 million people worldwide. A comparison article identifies nintedanib by the brand name Ofev and pirfenidone by the brand name Esbriet, and says both were approved in 2014 and slow disease progression. Another source specifies that the FDA approved Esbriet for IPF on October 15, 2014.
Balancing Benefits and Tolerability: Making Informed Decisions About Pirfenidone
Pirfenidone can be a valuable tool in managing IPF, but it's not without its challenges. The studies discussed here emphasize the importance of individualized treatment approaches and careful monitoring for side effects. Patients should openly communicate with their healthcare providers about any concerns or adverse events they experience.
Benefits and Tolerability
An expert panel review reports that pirfenidone reduces the decline in lung function and improves progression-free survival in IPF. It describes the treatment as generally well tolerated, while noting that a minority of patients discontinue it because of gastrointestinal and skin-related adverse events. A second review gives the same account of benefits and discontinuation-related side effects.
Emerging Treatments
A 2026 BMJ Medicine review says current pulmonary fibrosis treatment is limited to nintedanib and pirfenidone, which slow but do not halt or reverse disease progression. It reports that nerandomilast showed positive results in phase 3 trials and was approved in the United States in 2025 for IPF and progressive pulmonary fibrosis. A 2023 review describes pirfenidone and nintedanib as first-generation antifibrotics approved more than 10 years earlier that reduce the rate of progression.
Experience Outside Clinical Trials
A study in Taiwan set out to examine the real-world effectiveness and safety of pirfenidone in people with IPF. Its introduction says randomized controlled trials had demonstrated reduced lung-function decline and reduced risk of acute exacerbation among patients treated with pirfenidone. A 2016 real-world report says side effects are common outside the restrictions of clinical trials.
While the research indicates that women may experience less tolerance to pirfenidone and need lower doses, further studies with larger sample sizes are needed to confirm this finding. Dosage adjustments and proactive management of side effects can help improve treatment adherence and overall outcomes.
Ultimately, the decision to use pirfenidone should be made in consultation with a pulmonologist or other healthcare professional experienced in treating IPF. By weighing the potential benefits and risks, and by actively participating in their care, patients can make informed choices that best support their quality of life.